News & Press Releases Swedish

Scandinavian ChemoTech byter Certified Adviser till Redeye AB

Bolaget har ingått avtal med Redeye AB avseende tjänsten som Certified Adviser med tillträde den 1 december 2022. 

Read more

Scandinavian ChemoTechs Animal Care-division tecknar betydande kliniskt utvärderingsavtal med The Royal Veterinary College

Vetiqure AB är glada över att meddela undertecknandet av ett mycket viktigt avtal om klinisk utvärdering med The Royal Veterinary College (RVC) häst-team i London, Storbritannien. RVC är en av världens ledande specialiserade högre utbildningsinstitutioner för veterinärmedicin, biovetenskap och veterinärsköterska och rankades som världens främsta veterinärskola i QS World University Rankings 2022. Syftet med detta…

Read more

Scandinavian ChemoTech AB publicerar delårsrapport för januari-september 2022

Tredje kvartalet · Nettoomsättningen uppgick till 119 KSEK (9) · Resultat före skatt uppgick till -5 573 KSEK (- 5 732) · Resultat per aktie uppgick till -0,58 SEK (-0,65) · Kassaflöde från den löpande verksamheten uppgick till -5 286 KSEK KSEK (-7 014) Perioden 1 januari - 30 september · Nettoomsättningen uppgick till 246…

Read more

–

Read all news in Swedish

News & Press Releases English

Scandinavian ChemoTech changes Certified Adviser till Redeye AB

The Company has appointed Redeye AB as Certified Adviser with a start date of December 1st, 2022. 

Read more

Scandinavian ChemoTech’s Animal Care division signs significant Clinical Evaluation Agreement with The Royal Veterinary College

Vetiqure AB is excited to share the signing of a very important Clinical Evaluation Agreement with The Royal Veterinary College’s (RVC) Equine team in London, UK. The RVC is one of the world’s leading specialist higher education institutions for veterinary medicine, biosciences and veterinary nursing and was ranked as the world's No 1 veterinary school…

Read more

Important update regarding cancer patients treated with IQwave™ Tumour Specific Electroporation™ (TSE) at Ulis Hospital Ukraine

Scandinavian ChemoTech’s medical affairs team has received very encouraging updates on the two pancreatic cancer patients reported on in our press release on 19 September -22, and the patient with locally advanced squamous cell carcinoma that has been treated with TSE at Ulis Hospital in Ukraine. The previously published press release stated that one of…

Read more

–

Read all news in English

ChemoTech Videos

2022

ChemoTech Q2 2022 - Livestream Presentation (in Swedish)

SWECARE at EXPO 2020 DUBAI: "Closing Ceremony"

A conversation with Småbolagspodden

(Audio in Swedish)

I det senaste avsnittet av Småbolagspodden berättar Scandinavian ChemoTechs vd Mohan Frick om hur bolagets unika metod för cancerbehandling, via så kallad tumörspecifik elektroporation, ska hjälpa människor och djur världen över.

Lyssna på hela avsnittet här:
52. ChemoTech – Vill vara en kraft för skonsammare cancervård

2021

Presentation of Q3 - Analysera med oss November 2021 (Swedish)

ChemoTech presents for its upcoming Annual General meeting 24 May 2021. Spoken language is Swedish but the presentation is in English.

Innovative TSE technology increases the local effect of chemotherapy (Swedish)

ChemoTech answers questions from the shareholders; Part 1 (Swedish)

CEO Mohan Frick presenting at Erik Penser Bank Bolagsdag (Swedish)

Erik Penser Bank interview with CEO Mohan Frick (Swedish) 8 January 2021

Videos from 2020

Company Presentation of the Q3 report (Swedish) 11th of November 2020

Company Presentation (Swedish) 27th of October 2020

Videos from 2019

Share Day in Gothenburg, November 4 2019 (Swedish)

Videos from 2018

Share analysis ChemoTech Q2 2018 (Swedish)

Share Day in Malmö on May 22, 2018 (Swedish)

Our foundation

Our profound knowledge in electroporation forms the starting point for the company’s existing product and R&D projects: The IQwave™ specially designed for our TSE™ – Tumour Specific Electroporation technology which treats a range of various tumours.
READ MORE

Our research focus

Our aim is to document the effects of elctrochemotherapy for pain management for cancer patients, an area with significant unmet medical need.
READ MORE